Market access of pharmaceutical products in Germany is associated with numerous challenges, particularly around regulatory discussions. When the so-called Arzneimittelmarkt-Neuordnungsgesetz (AMNOG) was introduced in 2011, a significantly more rigorous benefit evaluation procedure was put into place. Since then it is more important than ever for pharmaceutical companies to strategically plan their market access communications and focus on stakeholder needs.
mehr
